Nasal and sinus cancer, or paranasal sinus and nasal cavity cancer, refers to malignant tumors that develop in the nasal cavity and paranasal sinuses. Alfa Cytology is a world leader in head and neck cancer research. With our extensive experience and advanced platform, we can provide the best services for nasal and sinus cancer.
Introduction to Nasal and Sinus Cancer
Compared to other types of cancer, nasal and sinus cancer are relatively rare. According to the American Cancer Society, nasal and sinus cancer accounts for less than 1% of all cancers diagnosed annually in the United States. The pathogenesis of nasal and sinus cancer includes genetic and environmental factors.
Targets of Nasal and Sinus Cancer Therapy Development
Some molecular targets in nasal and sinus cancer have been identified, providing opportunities for new therapy development, particularly targeted therapies and immunotherapies. The following are specific targets and current development status.
Epidermal Growth Factor Receptor (EGFR)
Overexpression or mutations in EGFR are common in nasal and sinus cancers. Targeting EGFR with monoclonal antibodies like cetuximab or small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib has shown promise in clinical trials.
Vascular Endothelial Growth Factor (VEGF)
Nasal and sinus cancers often exhibit increased VEGF expression, leading to tumor angiogenesis. Anti-VEGF therapies like bevacizumab have been explored in clinical trials to inhibit angiogenesis and tumor growth.
PI3K/AKT/mTOR Pathway
Inhibitors targeting this pathway, such as mTOR inhibitors (e.g., everolimus) and PI3K inhibitors (e.g., buparlisib), have been investigated as potential therapeutic options.
Therapy for Nasal and Sinus Cancer
Nasal and sinus cancer therapy involves multidisciplinary methods, such as surgery, radiation therapy, and chemotherapy. Recently, several emerging therapies have also shown promising prospects, including targeted therapy and immunotherapy.
Immunotherapy
Immunotherapy has shown great potential in nasal and sinus cancers. Immunotherapy aims to stimulate the immune system to recognize and attack cancer cells.
Targeted Therapies
Apart from targeting EGFR, several other targeted therapies are being evaluated.
Our Services
Nasal and sinus cancer is relatively rare, but it can have a significant impact on people. Therefore, Alfa Cytology is working on providing one-stop solutions for nasal and sinus cancer, including but not limited to the following.
Nasal and Sinus Cancer Modeling Platform
The following models can form tumors similar to human nasal and sinus cancers through genetic modification or chemical induction. Evaluate tumor growth, metastasis, therapy response, and molecular characteristics in these models to guide further research.
| Types of Model |
Optional Species |
|
- Mice
- Rats
- Non-human Primates
|
Alfa Cytology is committed to the research and study of laryngeal cancer, from immune checkpoint inhibitor development services, and cell therapy development services, to cancer drug development services, providing one-stop solutions. Our cancer experts have many years of experience in the latest therapies development for nasal and sinus cancer. If you are interested in our service, please contact us for more information.
For research use only.
Related Services
